TOKYO — OriCiroGenomics is a pioneer in cell-free DNA synthesis and amplification for genome-scale large-scale genetic therapy and synthetic biology. Today, the company announced that Shigemasa (“Shige”) Sasaki was appointed Chief Operating Officer/Chief Technology Officer and Nasir Kato Bashiruddin, Ph.D. as Chief Technology Officer. While Mr. Sasaki will be responsible for all aspects of the company, including marketing and sales functions as well as operations, Dr. Bashiruddin will be in charge of technology development at OriCiro.

“We are grateful to have Shige and Nasir as OriCiro moves from a developmental stage to a growth stage. Seiji Hirasaki is the Chief Executive Officer of OriCiro Genomics. “They bring both the leadership and expertise needed to succeed in each of these roles. We are confident that they will be instrumental in helping OriCiro achieve its goal to help our customers develop innovative products based upon our cell-free DNA technology.

He has more than 25 years experience in the life sciences industry. He has led teams in sales, marketing, and operations. He was the Asia Pacific Marketing Director for GE Healthcare where he was responsible to oversee sales of $300 million annually. Before joining OriCiro he was the President of the Japanese subsidiary Unchained Labs (a US-based research tool company), where he launched the Japanese operation. He is a graduate of Fukui Prefectural University with a BSc degree in bioengineering.

Dr. Bashiruddin has extensive experience in chemical biology and its application for drug discovery. Prior to OriCiro he was the Director of the Platform Innovation Group at PeptiDream. This peptide drug discovery company was a peptide-based drug discovery company. He managed and led many successful collaborations with pharma companies and biotech companies. He holds a Ph.D. from the University of Tokyo in chemistry and a BSc from the University of Washington in biology.

About OriCiro Genomics
OriCiro focuses on the commercialization and development of cell-free synthesis technology and amplification technology for genome-scale large genetic DNA for applications in gene and other cell-based therapies. OriCiro’s proprietary technology can unlock the potential of advanced therapy and synthetic biology by providing a powerful tool for research, development, and manufacturing in multiple industries, including pharmaceutical, diagnostics and agriculture. The company is based in Tokyo, Japan. For more information, please visit https://www.ec.oriciro.com/
Contact Shigemasa Sasaki Phone Number: +81-7044302005 e-mail: [emailprotected]
SOURCE OriCiro Genomics, Inc.

More dWeb.News Health at https://dweb.news/category/dweb-news/section-h-health-wellness-medical-news/

This article was authored by Daniel Webster using Artificial Intelligence. To learn more visit https://wordai.com/?ref=0b4438